probucol has been researched along with Coronary Artery Disease in 41 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Probucol has been recognized to have antioxidant properties as well as lipid-lowering effects, and may improve endothelial function." | 6.71 | Long-term treatment with probucol improves endothelial function in patients with coronary artery disease. ( Kimura, Y; Ono, H; Suzuki, S; Tagawa, T; Takeda, K; Urabe, Y, 2004) |
| "In this study, we integrated two randomized control trials, PROSPECTIVE and IMPACT, to address the effect of probucol on cerebrocardiovascular events and carotid intima-media thickness (IMT) in Japanese, Korean, and Chinese patients with coronary artery disease (CAD)." | 5.51 | Integrated Analysis of Two Probucol Trials for the Secondary Prevention of Atherosclerotic Cardiovascular Events: PROSPECTIVE and IMPACT. ( Arai, H; Bujo, H; Fukushima, M; Ge, J; Ishibashi, T; Kagimura, T; Kang, HJ; Kim, CH; Kim, MH; Kim, SH; Kita, T; Masuda, D; Matsuzawa, Y; Nakagawa, S; Oh, BH; Park, JE; Saito, Y; Sung, J; Tanabe, K; Yamashita, S, 2022) |
| "Hypercholesterolemic patients with coronary artery disease were randomized to three groups and received study drugs for 3 years: the control with statin alone; the probucol group with statin and probucol; and the combo group with statin, probucol, and cilostazol." | 5.41 | Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study. ( Ge, J; Kang, HJ; Kim, CH; Kim, MH; Kim, SH; Oh, BH; Park, JE; Sung, J, 2021) |
| " Both, the durable polymer zotarolimus-eluting stent (DP-ZES), the first DES to gain FDA-approval for specific use in patients with diabetes mellitus, and the polymer-free sirolimus- and probucol-eluting stent (PF-SES), with a unique design that enables effective drug release without the need of a polymer offer the potential to enhance clinical long-term outcomes especially in patients with diabetes mellitus." | 5.41 | Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy ( Aytekin, A; Cassese, S; Coughlan, JJ; Ibrahim, T; Joner, M; Kastrati, A; Kessler, T; Koch, T; Koppara, T; Kufner, S; Laugwitz, KL; Lenz, T; Schunkert, H; Wiebe, J; Xhepa, E, 2021) |
| "A 66-year-old male heterozygous familial hypercholesterolemia (FH) patient with significant coronary atherosclerosis has been treated by us with probucol (1000 mg daily) for eight years." | 5.29 | Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. ( Kajinami, K; Koizumi, J; Mabuchi, H; Nishitsuji, M; Shimizu, M; Takeda, Y, 1996) |
| " The powerful antioxidant probucol has been shown to prevent coronary restenosis after balloon angioplasty in the Multivitamins and Probucol (MVP) trial and other clinical studies." | 4.81 | Prevention of restenosis with antioxidants: mechanisms and implications. ( Grégoire, J; L'Allier, PL; Tardif, JC, 2002) |
| "A 62-year-old man with old myocardial infarction and familial hypercholesterolemia was treated by both probucol and low-density lipoprotein (LDL) apheresis." | 3.70 | Long-term effect of low-density lipoprotein apheresis in a patient with heterozygous familial hypercholesterolemia: follow-up study using coronary angiography. ( Arakawa, K; Jimi, S; Naito, S; Nii, T; Okabe, M; Saku, K; Shirai, K; Takeda, Y, 1998) |
| "The influence of probucol-induced low high-density lipoprotein (HDL) cholesterolemia on the progression of coronary atherosclerosis was studied in 320 patients with angina pectoris or myocardial infarction, 32 patients with probucol 500 mg/day, 288 patients without probucol, who underwent follow-up angiography at intervals of at least 2 years." | 3.69 | [Influence of low high-density lipoprotein cholesterolemia induced by probucol on the progression of coronary atherosclerosis]. ( Harada, S; Hiasa, Y; Hosokawa, S; Kato, S; Kishi, K; Ohtani, R; Takahashi, T; Tanimoto, M, 1997) |
| "Probucol has a potent antioxidative effect, inhibits the oxidation of LDL, and reduces xanthomas." | 2.82 | Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease. ( Arai, H; Bujo, H; Fukushima, M; Kagimura, T; Kita, T; Masuda, D; Matsuzaki, M; Matsuzawa, Y; Ohama, T; Saito, Y; Yamashita, S, 2016) |
| "Probucol has been recognized to have antioxidant properties as well as lipid-lowering effects, and may improve endothelial function." | 2.71 | Long-term treatment with probucol improves endothelial function in patients with coronary artery disease. ( Kimura, Y; Ono, H; Suzuki, S; Tagawa, T; Takeda, K; Urabe, Y, 2004) |
| "Probucol is a lipid-lowering drug that has an antioxidant effect." | 2.70 | Effect of antioxidant probucol for preventing stent restenosis. ( Cha, KS; Han, JY; Kim, HJ; Kim, JS; Kim, MH, 2002) |
| "Probucol (750 mg/day) was administered for at least 30 days prior to PTCA (34 patients, group P-1) or less than 14 days prior to PTCA (27 patients, group P-2)." | 2.68 | Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. ( Daida, H; Lee, YJ; Miyano, H; Mokuno, H; Sakurai, H; Takaya, J; Yamaguchi, H; Yokoi, H, 1996) |
| " AGI-1067 is the metabolically stable monosuccinic acid ester of probucol, and a potent phenolic antioxidant representing a novel class of orally bioavailable compounds termed vascular protectants." | 2.44 | AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis. ( Eisert, C; Malinin, A; Ong, S; Serebruany, VL, 2007) |
| "Probucol use was associated with significant decrease in all-cause death (hazard ratio [HR], 0." | 1.38 | Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis. ( Amano, A; Daida, H; Kajimoto, K; Kasai, T; Kubota, N; Miyauchi, K, 2012) |
| " In animals receiving pravastatin and the enriched diet (verum group; n = 6), mean total serum cholesterol levels were consistently lowered at a dosage of 5 mg/kg pravastatin and with the combined treatment." | 1.30 | Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet. ( Bräsen, JH; Harsch, M; Niendorf, A, 1998) |
| "Probucol treatment of corpulent male rats did not reduce plasma lipid concentrations or hyperinsulinemia." | 1.30 | Cardioprotective effect of probucol in the atherosclerosis-prone JCR:LA-cp rat. ( Amy, RM; Dolphin, PJ; Graham, SE; Russell, JC, 1998) |
| "Probucol prevented the increase in lipid peroxides, but had no effect on plasma cholesterol." | 1.29 | Preservation of endothelium-dependent relaxation in atherosclerotic rabbit aorta by probucol. ( Cohen, RA; Haudenschild, CC; Simon, BC, 1993) |
| "A 66-year-old male heterozygous familial hypercholesterolemia (FH) patient with significant coronary atherosclerosis has been treated by us with probucol (1000 mg daily) for eight years." | 1.29 | Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. ( Kajinami, K; Koizumi, J; Mabuchi, H; Nishitsuji, M; Shimizu, M; Takeda, Y, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.44) | 18.7374 |
| 1990's | 14 (34.15) | 18.2507 |
| 2000's | 13 (31.71) | 29.6817 |
| 2010's | 10 (24.39) | 24.3611 |
| 2020's | 3 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, HJ | 2 |
| Kim, MH | 3 |
| Sung, J | 2 |
| Kim, SH | 2 |
| Kim, CH | 2 |
| Park, JE | 2 |
| Ge, J | 2 |
| Oh, BH | 2 |
| Arai, H | 3 |
| Bujo, H | 2 |
| Masuda, D | 2 |
| Ishibashi, T | 1 |
| Nakagawa, S | 1 |
| Tanabe, K | 1 |
| Kagimura, T | 2 |
| Kita, T | 3 |
| Saito, Y | 3 |
| Fukushima, M | 2 |
| Matsuzawa, Y | 2 |
| Yamashita, S | 2 |
| Koch, T | 1 |
| Lenz, T | 1 |
| Joner, M | 1 |
| Xhepa, E | 1 |
| Koppara, T | 1 |
| Wiebe, J | 2 |
| Coughlan, JJ | 1 |
| Aytekin, A | 1 |
| Ibrahim, T | 3 |
| Kessler, T | 1 |
| Cassese, S | 2 |
| Laugwitz, KL | 3 |
| Schunkert, H | 1 |
| Kastrati, A | 3 |
| Kufner, S | 2 |
| Krackhardt, F | 1 |
| Rosli, MA | 1 |
| Leschke, M | 1 |
| Schneider, A | 1 |
| Sperling, C | 1 |
| Heang, TM | 1 |
| Pons, M | 1 |
| Sousa, PJ | 1 |
| Kherad, B | 1 |
| Waliszewski, M | 1 |
| Ko, YG | 2 |
| Choi, SH | 2 |
| Chol Kang, W | 1 |
| Kwon Lee, B | 1 |
| Wook Kim, S | 1 |
| Shim, WH | 2 |
| Lankin, V | 1 |
| Konovalova, G | 1 |
| Tikhaze, A | 1 |
| Shumaev, K | 1 |
| Kumskova, E | 1 |
| Viigimaa, M | 1 |
| Ohama, T | 1 |
| Matsuzaki, M | 1 |
| Sorges, J | 1 |
| Mehilli, J | 2 |
| Repp, J | 1 |
| Lohaus, R | 1 |
| Lahmann, A | 1 |
| Rheude, T | 1 |
| Massberg, S | 2 |
| Byrne, RA | 2 |
| Serebruany, V | 1 |
| Malinin, A | 2 |
| Qiu, FH | 1 |
| Xu, XC | 1 |
| Kunsch, C | 2 |
| Scott, R | 2 |
| Kim, BK | 1 |
| Lee, BK | 1 |
| Kang, WC | 1 |
| Kim, SW | 1 |
| Lee, JH | 1 |
| Lee, M | 1 |
| Honda, Y | 1 |
| Fitzerald, PJ | 1 |
| Schulz, S | 1 |
| Pache, J | 1 |
| Hausleiter, J | 1 |
| Fusaro, M | 1 |
| Ott, I | 1 |
| Schömig, A | 1 |
| Kasai, T | 1 |
| Miyauchi, K | 1 |
| Kubota, N | 1 |
| Kajimoto, K | 1 |
| Amano, A | 1 |
| Daida, H | 2 |
| Kajinami, K | 2 |
| Akao, H | 1 |
| Chen, SL | 1 |
| Ye, F | 1 |
| Zhang, JJ | 1 |
| Zou, JJ | 1 |
| Qian, XS | 1 |
| Li, F | 1 |
| Yang, S | 1 |
| Ge, Z | 1 |
| Shan, SJ | 1 |
| Li, XB | 1 |
| Xu, T | 1 |
| Kan, J | 1 |
| Lin, L | 1 |
| Han, YL | 1 |
| Cha, KS | 1 |
| Han, JY | 1 |
| Kim, HJ | 1 |
| Kim, JS | 1 |
| Wasserman, MA | 1 |
| Sundell, CL | 1 |
| Edwards, D | 1 |
| Meng, CQ | 1 |
| Medford, RM | 1 |
| Gotto, AM | 1 |
| Tardif, JC | 4 |
| Grégoire, J | 4 |
| Lavoie, MA | 2 |
| L'Allier, PL | 4 |
| Tagawa, T | 1 |
| Urabe, Y | 1 |
| Kimura, Y | 1 |
| Suzuki, S | 1 |
| Ono, H | 1 |
| Takeda, K | 1 |
| Ibrahim, R | 1 |
| Anderson, TJ | 2 |
| Reeves, F | 1 |
| Title, LM | 1 |
| Schampaert, E | 1 |
| LeMay, M | 1 |
| Lespérance, J | 1 |
| Guertin, MC | 1 |
| Brennan, ML | 1 |
| Hazen, SL | 1 |
| Bertrand, OF | 1 |
| Serebruany, VL | 1 |
| Eisert, C | 1 |
| Ong, S | 1 |
| Douglas, JS | 1 |
| Simon, BC | 1 |
| Haudenschild, CC | 1 |
| Cohen, RA | 1 |
| Meredith, IT | 1 |
| Yeung, AC | 1 |
| Frei, B | 1 |
| Selwyn, AP | 1 |
| Ganz, P | 1 |
| Lankin, VZ | 3 |
| Revenko, VM | 3 |
| Lupanov, VP | 3 |
| Tikhaze, AK | 3 |
| Liakishev, AA | 2 |
| Kukharchuk, VV | 2 |
| Nishitsuji, M | 1 |
| Takeda, Y | 2 |
| Shimizu, M | 1 |
| Koizumi, J | 1 |
| Mabuchi, H | 1 |
| Lee, YJ | 1 |
| Yokoi, H | 1 |
| Miyano, H | 1 |
| Takaya, J | 1 |
| Sakurai, H | 1 |
| Mokuno, H | 1 |
| Yamaguchi, H | 1 |
| Takahashi, T | 1 |
| Hiasa, Y | 1 |
| Harada, S | 1 |
| Hosokawa, S | 1 |
| Kato, S | 1 |
| Tanimoto, M | 1 |
| Kishi, K | 1 |
| Ohtani, R | 1 |
| Mikhin, VP | 1 |
| Saku, K | 1 |
| Jimi, S | 1 |
| Okabe, M | 1 |
| Shirai, K | 1 |
| Nii, T | 1 |
| Naito, S | 1 |
| Arakawa, K | 1 |
| Bräsen, JH | 1 |
| Harsch, M | 1 |
| Niendorf, A | 1 |
| Russell, JC | 1 |
| Graham, SE | 1 |
| Amy, RM | 1 |
| Dolphin, PJ | 1 |
| Fukuzawa, S | 1 |
| Ozawa, S | 1 |
| Inagaki, M | 1 |
| Morooka, S | 1 |
| Inoue, T | 1 |
| Yagyu, H | 1 |
| Senior, K | 1 |
| Yokode, M | 1 |
| Ishii, K | 1 |
| Kume, N | 1 |
| Nagano, Y | 1 |
| Otani, H | 1 |
| Ueda, Y | 1 |
| Hara, S | 1 |
| Tatami, R | 1 |
| Inoue, N | 1 |
| Itoh, H | 1 |
| Kishino, B | 1 |
| Koga, N | 1 |
| Nakashima, Y | 1 |
| Nishide, T | 1 |
| Okamura, K | 1 |
| Teramoto, T | 1 |
| Forti, N | 1 |
| Dereviacki, BE | 1 |
| Giannini, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis[NCT00598533] | Phase 4 | 3,002 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Coroflex ISAR 2000 Postmarket Surveillance Non-Interventional Study[NCT02629575] | 2,877 participants (Actual) | Observational [Patient Registry] | 2014-01-31 | Completed | |||
| [NCT01031667] | Phase 4 | 118 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Coroflex ISAR 2000 Extended Postmarket Surveillance Non-Interventional Study[NCT02905214] | 4,369 participants (Actual) | Observational | 2016-01-31 | Completed | |||
| Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465] | Phase 4 | 50 participants (Actual) | Interventional | 2017-02-16 | Completed | ||
| Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study[NCT01291641] | Phase 4 | 342 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [NCT00005681] | 0 participants | Observational | 1989-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for probucol and Coronary Artery Disease
| Article | Year |
|---|---|
Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease.
Topics: Antioxidants; Arteriosclerosis; Cardiovascular System; Coronary Artery Disease; Humans; Probucol; Si | 2003 |
Antioxidants, statins, and atherosclerosis.
Topics: Animals; Antioxidants; Ascorbic Acid; beta Carotene; Clinical Trials as Topic; Coronary Artery Disea | 2003 |
Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Clinical Trials as Topic; Coronary | 2003 |
Prevention of restenosis with antioxidants: mechanisms and implications.
Topics: Angioplasty, Balloon, Coronary; Antioxidants; Clinical Trials as Topic; Coronary Artery Disease; Cor | 2002 |
Vascular protectants for the treatment of atherosclerosis.
Topics: Antioxidants; Coronary Artery Disease; Humans; Probucol; Protective Agents; Randomized Controlled Tr | 2003 |
AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Platelets; Coronary Artery Disease; Coronary Restenosi | 2007 |
Pharmacologic approaches to restenosis prevention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease | 2007 |
[Probucol].
Topics: Angioplasty, Balloon, Coronary; Animals; Antioxidants; Arteriosclerosis; Clinical Trials as Topic; C | 2001 |
[The value of chemotherapeutic intervention on primary hyperlipidemias in the prevention of coronary arteriosclerosis].
Topics: Adult; Cholesterol; Clinical Trials as Topic; Colestipol; Coronary Artery Disease; Humans; Hyperlipi | 1988 |
17 trials available for probucol and Coronary Artery Disease
16 other studies available for probucol and Coronary Artery Disease
| Article | Year |
|---|---|
Propensity score matched all comers population treated with ultra-thin strut bare metal and sirolimus-probucol coated drug-eluting stents of identical stent architecture.
Topics: Aged; Aged, 80 and over; Asia; Cardiovascular Agents; Coronary Artery Disease; Drug-Eluting Stents; | 2018 |
The initiation of free radical peroxidation of low-density lipoproteins by glucose and its metabolite methylglyoxal: a common molecular mechanism of vascular wall injure in atherosclerosis and diabetes.
Topics: Adult; Aged; Coronary Artery Disease; Diabetes Mellitus; Female; Glucose; Humans; Lipid Peroxidation | 2014 |
Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Chi-Square Distribution; Coronary Ar | 2012 |
Probucol: can we step forward in atherosclerosis prevention with an old drug?
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Coronary Artery Bypass; Coronary Artery Di | 2012 |
Preservation of endothelium-dependent relaxation in atherosclerotic rabbit aorta by probucol.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Body Weight; Calcimycin; Cholesterol; Coronary Artery Disea | 1993 |
[The effect of long-term probucol intake on the lipoprotein cholesterol content and glutathione peroxidase activity in the blood of patients with coronary arteriosclerosis and hyperlipidemia].
Topics: Cholesterol, HDL; Cholesterol, LDL; Chronic Disease; Coronary Artery Disease; Drug Evaluation; Femal | 1993 |
Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary A | 1996 |
[Influence of low high-density lipoprotein cholesterolemia induced by probucol on the progression of coronary atherosclerosis].
Topics: Aged; Angina Pectoris; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery | 1997 |
[The antioxidant probucol as a regulator of the intensity of free-radical lipid peroxidation processes in the blood of patients with coronary atherosclerosis].
Topics: Antioxidants; Chronic Disease; Coronary Artery Disease; Drug Evaluation; Female; Free Radicals; Glut | 1997 |
Long-term effect of low-density lipoprotein apheresis in a patient with heterozygous familial hypercholesterolemia: follow-up study using coronary angiography.
Topics: Anticholesteremic Agents; Blood Component Removal; Coronary Angiography; Coronary Artery Disease; Fo | 1998 |
Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet.
Topics: Animals; Aorta; Cholesterol; Cholesterol, Dietary; Coronary Artery Disease; Drug Therapy, Combinatio | 1998 |
Cardioprotective effect of probucol in the atherosclerosis-prone JCR:LA-cp rat.
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Blood Glucose; Coronary Artery Disease; Coronary | 1998 |
Secondary prevention with lipid lowering therapy in familial hypercholesterolemia: a correlation between new evolution of stenotic lesion and achieved cholesterol levels after revascularization procedures.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholestyramine Resin; Coronary Arter | 1999 |
Drug reverses coronary atherosclerosis.
Topics: Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Coronary Vess | 2002 |
The role of oxidized lipoproteins in the pathogenesis of atherosclerosis.
Topics: Animals; Apolipoproteins B; Cholesterol Esters; Cholestyramine Resin; Coronary Artery Disease; Lipop | 1992 |
[Changes of blood antioxidative enzyme activity and lipid levels in patients with coronary atherosclerosis treated with probucol].
Topics: Coronary Artery Disease; Female; Glutathione Peroxidase; Humans; Lipids; Male; Oxidoreductases; Prob | 1991 |